Literature DB >> 32339915

Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19.

Gavin Giovannoni1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32339915      PMCID： PMC7165093          DOI： 10.1016/j.msard.2020.102135

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN： 2211-0348            Impact factor:   4.339


× No keyword cloud information.
  23 in total

1.  Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD.

Authors:  Sara Esmaeili; Mohammad Hossein Abbasi; Meysam Abolmaali; Mohammad Mojtahed; Seyedeh Niloufar Rafiei Alavi; Sevim Soleimani; Mahisa Mokhtari; Jaber Hatam; Samaneh Tanhapour Khotbehsara; Mohammad Reza Motamed; Mohammad Taghi Joghataei; Zahra Mirzaasgari; Mehdi Moghaddasi
Journal:  BMC Neurol       Date:  2021-05-01       Impact factor: 2.474

2.  COVID-19 in persons with multiple sclerosis treated with ocrelizumab - A pharmacovigilance case series.

Authors:  Richard Hughes; Rosetta Pedotti; Harold Koendgen
Journal:  Mult Scler Relat Disord       Date:  2020-05-16       Impact factor: 4.339

3.  SARS-CoV-2 infection and seroprevalence in patients with multiple sclerosis.

Authors:  R Piñar Morales; M A Ramírez Rivas; F J Barrero Hernández
Journal:  Neurologia (Engl Ed)       Date:  2021-06-01

4.  COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies.

Authors:  Virginia Meca-Lallana; Clara Aguirre; Laura Cardeñoso; Teresa Alarcon; José Vivancos
Journal:  Mult Scler Relat Disord       Date:  2020-06-15       Impact factor: 4.339

5.  Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain.

Authors:  Paloma Montero-Escribano; Jorge Matías-Guiu; Patricia Gómez-Iglesias; Jesús Porta-Etessam; Vanesa Pytel; Jordi A Matias-Guiu
Journal:  Mult Scler Relat Disord       Date:  2020-05-07       Impact factor: 4.339

6.  Low symptomatic COVID-19 in an elderly patient with follicular lymphoma treated with rituximab-based immunotherapy: A case report.

Authors:  Stanisław Łącki; Kinga Wyżgolik; Michał Nicze; Sylwia Georgiew-Nadziakiewicz; Jerzy Chudek; Kamil Wdowiak
Journal:  World J Clin Cases       Date:  2021-06-26       Impact factor: 1.337

7.  Management of Idiopathic CNS inflammatory diseases during the COVID-19 pandemic: Perspectives and strategies for continuity of care from a South East Asian Center with limited resources.

Authors:  S Viswanathan
Journal:  Mult Scler Relat Disord       Date:  2020-07-03       Impact factor: 4.339

8.  Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal.

Authors:  Victor Gomez-Mayordomo; Paloma Montero-Escribano; Jordi A Matías-Guiu; Nuria González-García; Jesús Porta-Etessam; Jorge Matías-Guiu
Journal:  J Med Virol       Date:  2020-07-15       Impact factor: 20.693

9.  Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.

Authors:  Mahsa Ghajarzadeh; Omid Mirmosayyeb; Mahdi Barzegar; Nasim Nehzat; Saeed Vaheb; Vahid Shaygannejad; Amir-Hadi Maghzi
Journal:  Mult Scler Relat Disord       Date:  2020-05-23       Impact factor: 4.339

Review 10.  The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.

Authors:  David Baker; Sandra Amor; Angray S Kang; Klaus Schmierer; Gavin Giovannoni
Journal:  Mult Scler Relat Disord       Date:  2020-05-12       Impact factor: 4.339
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.